
Index Ventures closes life sciences fund at €150m
Index Ventures has closed its latest life sciences fund, raising тЌ150m from LPs and pharmaceutical companies.
Investors
Investors in the fund include previous LPs and pharmaceutical companies GlaxoSmithKline and Johnson & Johnson. The latter will join a scientific advisory board to provide advice on prospective investments.
Investments
The fund intends make investments in companies with one or two projects with first-in-class or best-in-class mechanisms of action and targets of unmet medical need. It will primarily operate within Europe, but considers American opportunities as well.
People
Partner Francesco de Rubertis worked on fundraising for Index Ventures.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds